AKBM – Offer under Employee Share Purchase Program and share capital increase

26 Feb 2026 21:12 CET

26 Feb 2026: Aker BioMarine ASA (the "Company") has renewed its offer of new
shares to employees in the Company and its Norwegian subsidiaries on similar
terms as for the last 3 previous years (the "Employee Share Purchase Program").
The deadline for acceptance of the offer in the Employee Share Purchase Program
expired on 26 Feb 2026, at 16:30 CET.

The offer price for the shares in the Employee Share Purchase Program has been
set to approximately NOK 83,01 (the "Offer Price"). The Offer Price is based on
the volume-weighted average share price for the Company's shares on the Oslo
Stock Exchange during the last five trading days prior to, and including, the
last day of the application period, with a discount of 20%. Any shares acquired
in the Employee Share Purchase Program will be subject to a lock-up period of
two years, and the reduced offer price shall reflect the value-reducing effect
of the lock-up period.

Based on the applications received in the Employee Share Purchase Program, the
board of directors of the Company has allocated a total of 20,127 new shares to
the participants in the Employee Share Purchase Program (the "Program Shares").

Furthermore, the board of directors has, on the basis of the authorisation
granted to it by the annual general meeting held on 25 April 2025, resolved to
increase the share capital of the Company with NOK 120 762, by issuance of
20,127 new shares, each with a nominal value of NOK 6.00, at a subscription
price equal to the Offer Price. The Program Shares comprise approximately 0.01%
of the existing and outstanding shares in the Company prior to their issuance.

Following the registration of the share capital increase with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret), the new share
capital of the Company will be NOK 526 341 156, divided into 87 703 399 shares,
each with a nominal value of NOK 6.00.


For further information, please contact
Lars Jacobsen, General Counsel
Mobile: +47 906 05 306
Email: lars.jacobsen@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine:
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.

More information:
Access the news on Oslo Bors NewsWeb site